Michael Ward, APRN, AGACNP-BC

Aging is inevitable. Preventable decline is not.

A review of GLP-1-based therapies found weight loss can include meaningful lean-mass loss, though estimates vary and clinical significance is uncertain. Muscle-protective habits still matter. pubmed.ncbi.nlm.nih.gov/3893… What should every weight-loss plan monitor?

During weight loss, protect lean mass with resistance training, adequate protein, recovery, and a sensible rate of loss. Scale weight alone cannot tell you what changed. Are you tracking strength or body composition too?

Weight loss is not automatically health gain. The better goal is improved metabolic health while preserving muscle, function, and a sustainable relationship with food. What outcome beyond the scale matters most to you?

A systematic review found balance training improves balance in healthy older adults, but programs varied widely. The best protocol is still uncertain. pubmed.ncbi.nlm.nih.gov/3508… Would you add 10 minutes twice weekly?

Balance training should be specific: narrow stance, single-leg work, reaching, stepping, turning, and reacting. Begin with support and progress gradually. Which balance task feels challenging but safe for you?

Independence is built before it is threatened. Strength, balance, confidence, and a safe environment all contribute. What part of independence matters most to you as you age?

A 2026 meta-analysis of 25 cohorts found higher social participation was associated with lower mortality (adjusted HR about 0.78). Observational data cannot prove participation caused the difference. pubmed.ncbi.nlm.nih.gov/4264… Where do you feel most connected?

Social health deserves a place in a longevity plan. Consider three questions: Who can you call in a crisis? Who do you have fun with? Where do you contribute? Which answer feels strongest, and which needs work?

Community is a health behavior. Being known, needed, and connected changes how we experience stress and how we care for ourselves. Who could use a call, meal, walk, or invitation from you this week?

A 2025 review of creatine and cognition in older adults found limited, mixed evidence: only six studies, with methodological quality often fair or poor. Promising is not the same as proven. pubmed.ncbi.nlm.nih.gov/4097… What level of evidence changes your behavior?

Before trying a peptide or emerging therapy, ask: Is it approved for this use? Are there human outcome data? Who manufactured it? What are the risks, alternatives, and monitoring plan? Which question is most often skipped?

The most exciting intervention is not always the most useful one. Novelty attracts attention; durable habits create outcomes. What simple health practice have you overlooked because it felt too ordinary?

A 2024 meta-analysis in older adults found HIIT and moderate continuous training produced broadly similar cardiometabolic effects; some higher-quality trials favored HIIT for fitness. pubmed.ncbi.nlm.nih.gov/3871… Which approach would you sustain?

Intervals can be simple: after warming up, alternate 1 minute hard with 2 minutes easy for 4-6 rounds. The right intensity is personal, especially with medical conditions. What form of cardio do you enjoy enough to repeat?

Doing hard things on purpose can expand what we believe we are capable of. The dose matters: enough challenge to adapt, not so much that recovery collapses. Where in your life would a little more productive discomfort help?

NAMS states hormone therapy is the most effective treatment for vasomotor symptoms and helps prevent bone loss. Benefits and risks vary by age, timing, route, and history. pubmed.ncbi.nlm.nih.gov/3579… What should shared decision-making include?

Menopause care can include sleep, resistance training, protein, bone health, cardiometabolic risk, sexual health, and symptom treatment. Hormone therapy is one tool, not the whole plan. Which domain is most often overlooked?

Women deserve precise, individualized conversations about midlife health, not fear-based headlines or one-size-fits-all answers. What menopause question do you wish received a clearer answer?

Genetic, epidemiologic, and trial evidence supports LDL as a causal driver of atherosclerotic disease. The question is how much lowering fits each person's risk. pubmed.ncbi.nlm.nih.gov/2844… Do you know your lifetime risk?

LDL-C is useful, but ApoB can better reflect the number of atherogenic particles when triglycerides, insulin resistance, or metabolic disease complicate the picture. Have you ever discussed ApoB with your clinician?